JP2011502177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502177A5 JP2011502177A5 JP2010532406A JP2010532406A JP2011502177A5 JP 2011502177 A5 JP2011502177 A5 JP 2011502177A5 JP 2010532406 A JP2010532406 A JP 2010532406A JP 2010532406 A JP2010532406 A JP 2010532406A JP 2011502177 A5 JP2011502177 A5 JP 2011502177A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- liposome
- therapeutic agent
- compound
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 claims 35
- 239000003814 drug Substances 0.000 claims 29
- 229940124597 therapeutic agent Drugs 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000002632 lipids Chemical class 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 239000002202 Polyethylene glycol Substances 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 13
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 10
- 230000001093 anti-cancer Effects 0.000 claims 9
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 190000008236 carboplatin Chemical compound 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 231100000632 Spindle poison Toxicity 0.000 claims 3
- 229930013930 alkaloid Natural products 0.000 claims 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 3
- 229940100198 alkylating agent Drugs 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 239000013059 antihormonal agent Substances 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000008512 biological response Effects 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 239000002532 enzyme inhibitor Substances 0.000 claims 3
- 229940125532 enzyme inhibitor Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 229940043355 kinase inhibitor Drugs 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 3
- 239000003504 photosensitizing agent Substances 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- 238000010792 warming Methods 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2007/003129 WO2009059450A1 (en) | 2007-11-05 | 2007-11-05 | Peptide ligand directed drug delivery |
| PCT/CN2008/001847 WO2009062399A1 (en) | 2007-11-05 | 2008-11-05 | Peptide ligand directed drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502177A JP2011502177A (ja) | 2011-01-20 |
| JP2011502177A5 true JP2011502177A5 (enExample) | 2011-12-22 |
Family
ID=40625344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532406A Pending JP2011502177A (ja) | 2007-11-05 | 2008-11-05 | ペプチドリガンドによる指向性ドラッグデリバリー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110200527A1 (enExample) |
| EP (1) | EP2215107B1 (enExample) |
| JP (1) | JP2011502177A (enExample) |
| CN (1) | CN101855237B (enExample) |
| WO (2) | WO2009059450A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| GB0814960D0 (en) * | 2008-08-15 | 2008-09-24 | Ge Healthcare As | Method for detecting dysplasia |
| BRPI1007466A2 (pt) | 2009-01-28 | 2018-06-12 | Smartcells Inc | conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba |
| JP5508438B2 (ja) | 2009-01-28 | 2014-05-28 | スマートセルズ・インコーポレイテツド | 制御された薬物送達のための複合体に基づくシステム |
| AU2010208305A1 (en) | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| CA2750223A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
| AU2010226243A1 (en) | 2009-03-20 | 2011-09-22 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| PL2542590T5 (pl) * | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych |
| CA2805739A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| US9068013B2 (en) | 2010-07-28 | 2015-06-30 | Smart Cells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| CA2806399A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| CN102351941B (zh) * | 2011-06-08 | 2014-07-16 | 中国科学院上海应用物理研究所 | 对功能分子进行18f标记的方法 |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US9011903B2 (en) | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| CN107082747B (zh) * | 2011-06-08 | 2020-11-20 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| WO2013123407A1 (en) * | 2012-02-17 | 2013-08-22 | Celsion Corporation | Thermosensitive nanoparticle formulations and method of making the same |
| US20130261444A1 (en) * | 2012-03-28 | 2013-10-03 | The Uab Research Foundation | Photothermal nanostructures in tumor therapy |
| CN104379158A (zh) * | 2012-04-10 | 2015-02-25 | 加利福尼亚大学董事会 | 双聚合物脂-肽缀合物及其纳米颗粒 |
| US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| CN102875647B (zh) * | 2012-09-10 | 2014-11-19 | 上海交通大学 | 与cd40l蛋白特异性结合的配体多肽及药物输送系统 |
| EP3024441A4 (en) * | 2013-07-25 | 2017-04-19 | Nemucore Medical Innovations, Inc. | Nanoemulsions of hydrophobic platinum derivative |
| MX366852B (es) | 2013-10-04 | 2019-07-25 | Merck Sharp & Dohme | Conjugados de insulina sensibles a glucosa. |
| WO2016026458A1 (zh) | 2014-08-22 | 2016-02-25 | 亚飞（上海）生物医药科技有限公司 | 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途 |
| CN104262455B (zh) * | 2014-08-22 | 2017-05-03 | 亚飞（上海）生物医药科技有限公司 | 肿瘤微环境靶向激活的紫杉醇衍生物及其制备和用途 |
| US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| CN107530291A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 双重负载的脂质体药物制剂 |
| CN104825394B (zh) * | 2015-04-17 | 2018-08-17 | 北京大学 | 靶向肿瘤相关成纤维细胞的脂质体载药系统 |
| KR20180027532A (ko) * | 2015-07-10 | 2018-03-14 | 펩티노보 바이오파마, 엘엘씨 | 소수성 약물의 효능 개선용 제형 |
| US10428111B2 (en) | 2015-09-12 | 2019-10-01 | Mahmoud Reza Jaafari | Cancer targeting by anti-EGFR peptides and applications thereof |
| US11001050B2 (en) * | 2016-04-20 | 2021-05-11 | Hewlett-Packard Development Company, L.P. | Material sets |
| US20200030411A1 (en) * | 2016-09-21 | 2020-01-30 | Agency For Science, Technology And Research | Methods and Compositions for Inhibiting Skin Inflammation and Determining Cancer Susceptibility |
| CN108635593B (zh) * | 2018-05-21 | 2022-03-11 | 天津科技大学 | 一种e-选择素肽配体修饰的靶向热敏脂质体的制备和应用 |
| JP6997862B2 (ja) | 2018-08-21 | 2022-02-10 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
| AU2023375892A1 (en) * | 2022-11-07 | 2025-04-03 | Ocugen, Inc. | Treatment of neurological disorder using nhr |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| JP4413617B2 (ja) * | 2001-12-12 | 2010-02-10 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化 |
| RU2196604C1 (ru) * | 2001-12-21 | 2003-01-20 | Северин Евгений Сергеевич | Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе |
| US20040248800A1 (en) * | 2003-03-20 | 2004-12-09 | Shane Atwell | Crystals and structures of epidermal growth factor receptor kinase domain |
| CN100356981C (zh) * | 2004-03-31 | 2007-12-26 | 上海新世界基因技术开发有限公司 | 与人表皮生长因子受体egfr特异性结合的配体寡肽 |
| CN100430092C (zh) * | 2004-06-03 | 2008-11-05 | 上海交通大学 | 用于基因及多肽药物粘膜给药的脂质复合物及其制备方法 |
| US20070092558A1 (en) * | 2005-10-20 | 2007-04-26 | George Heavner | Methods of Preparing Targeted Immunoliposomes |
| US20080146511A1 (en) * | 2006-12-14 | 2008-06-19 | Fundacao Oswaldo Cruz - Fiocruz | Selection method of peptides, peptides, method and kit of infection identification by mycobacterium leprae, pharmaceutical or immunological compositions containing peptides of mycobacterium leprae or sequences functionally equivalent |
-
2007
- 2007-11-05 WO PCT/CN2007/003129 patent/WO2009059450A1/en not_active Ceased
-
2008
- 2008-11-05 WO PCT/CN2008/001847 patent/WO2009062399A1/en not_active Ceased
- 2008-11-05 CN CN200880114789.6A patent/CN101855237B/zh not_active Expired - Fee Related
- 2008-11-05 JP JP2010532406A patent/JP2011502177A/ja active Pending
- 2008-11-05 EP EP08849427A patent/EP2215107B1/en not_active Not-in-force
- 2008-11-05 US US12/741,348 patent/US20110200527A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502177A5 (enExample) | ||
| Aloss et al. | Recent preclinical and clinical progress in liposomal doxorubicin | |
| Parodi et al. | Albumin nanovectors in cancer therapy and imaging | |
| Bulbake et al. | Liposomal formulations in clinical use: an updated review | |
| Lu et al. | Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery | |
| Al-Ahmady et al. | Lipid–peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo | |
| Mastrotto et al. | In vitro and in vivo behavior of liposomes decorated with PEGs with different chemical features | |
| Perche et al. | Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting | |
| Cheng et al. | Activable cell-penetrating peptide conjugated prodrug for tumor targeted drug delivery | |
| JP2013506411A5 (enExample) | ||
| JP2010503386A5 (enExample) | ||
| Bhupathiraju et al. | Synthesis and in vitro evaluation of BBB permeability, tumor cell uptake, and cytotoxicity of a series of carboranylporphyrin conjugates | |
| Al‐Ahmady et al. | Triggered doxorubicin release in solid tumors from thermosensitive liposome‐peptide hybrids: Critical parameters and therapeutic efficacy | |
| Davoodi et al. | Internalizing RGD, a great motif for targeted peptide and protein delivery: a review article | |
| JP2013121977A5 (enExample) | ||
| Motamarry et al. | Thermosensitive liposomes | |
| Li et al. | PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer | |
| WO2008100482A3 (en) | Peptides that target to tumor blood vessels of lung cancer and applications thereof | |
| KR20150062652A (ko) | 초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법 | |
| Checa-Chavarria et al. | Development of a prodrug of camptothecin for enhanced treatment of glioblastoma multiforme | |
| Li et al. | Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy | |
| Zhou et al. | A novel tri‐functional liposome Re‐educates “Cold Tumor” and abrogates tumor growth by synergizing autophagy inhibition and PD‐L1 blockade | |
| JP2009541319A5 (enExample) | ||
| AU2018254263B2 (en) | Fusogenic liposomes, compositions, kits and use thereof for treating cancer | |
| Hoshi et al. | Alternative strategies for delivering immunotherapeutics targeting the PD-1/PD-L1 immune checkpoint in cancer |